Cart
sales@molnova.com
[Pyr4] - MBP (4 - 14)
CAS No. 136132-68-8
[Pyr4] - MBP (4 - 14)( ——— )
Catalog No. M41369 CAS No. 136132-68-8
[pGlu4]-Myelin Basic Protein (4-14) is the phosphorylated 4-14 fragment (EKRPSQRSKYL) of myelin basic protein (MBP). [pGlu4]-Myelin Basic Protein (4-14) surrounds the serine residue in position 8 of the myelin basic protein.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 25MG | Get Quote | Get Quote |
|
| 50MG | Get Quote | Get Quote |
|
| 100MG | Get Quote | Get Quote |
|
Biological Information
-
Product Name[Pyr4] - MBP (4 - 14)
-
NoteResearch use only, not for human use.
-
Brief Description[pGlu4]-Myelin Basic Protein (4-14) is the phosphorylated 4-14 fragment (EKRPSQRSKYL) of myelin basic protein (MBP). [pGlu4]-Myelin Basic Protein (4-14) surrounds the serine residue in position 8 of the myelin basic protein.
-
Description[pGlu4]-Myelin Basic Protein (4-14) is the phosphorylated 4-14 fragment (EKRPSQRSKYL) of myelin basic protein (MBP). [pGlu4]-Myelin Basic Protein (4-14) surrounds the serine residue in position 8 of the myelin basic protein.
-
In Vitro———
-
In Vivo———
-
Synonyms———
-
PathwayOthers
-
TargetOther Targets
-
Recptor———
-
Research Area———
-
Indication———
Chemical Information
-
CAS Number136132-68-8
-
Formula Weight1391.61
-
Molecular FormulaC60H100N20O17
-
Purity>98% (HPLC)
-
Solubility———
-
SMILES———
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Durocher Y, et al. Activation of an 85 kDa ribosomal S6 kinase during serotonin-induced oocyte maturation. Int J Dev Biol. 1996 Jun;40(3):557-66. ?
molnova catalog
related products
-
Cholecystokinin Octa...
Cholecystokinin Octapeptide (1-5) (desulfated)
-
Ro 31-8220 Mesylate
Ro 31-8220 is a pan-PKC inhibitor for PKC-α/βI/βII/γ/ε (IC50: 5/24/14/27/24 nM), and also shows potent inhibition against MSK1, MAPKAP-K1b, S6K1, and GSK3β.
-
Copper histidine
Copper histidine inhibited Ctr1-mediated cellular uptake of oxaliplatin in vitro without altering oxaliplatin accumulation of platinum or neurotoxicity in DRG tissues in vivo.
